Metabolic and weight-management research

Semaglutide and tirzepatide have the strongest human evidence in this group because FDA-approved medicines containing these ingredients have been tested in large randomized trials for specific medical indications. Those trials studied appetite, body weight, blood sugar, and cardiometabolic outcomes under clinical supervision.

Retatrutide is being studied as a triple-receptor agonist. A phase 2 obesity trial reported substantial average weight reduction over 48 weeks, and a 2026 phase 3 trial reported 40-week results in adults with type 2 diabetes inadequately controlled by diet and exercise. Retatrutide nevertheless remains investigational while additional later-stage studies continue. FDA's current public safety page says retatrutide is not an approved drug, has not been found safe and effective for any condition, and cannot be used in compounding under federal law. That reinforces the boundary between a published trial and a vendor research-vial listing.

• Semaglutide: human evidence for appetite regulation, weight management, and glucose control in approved products and indications.
• Tirzepatide: human evidence for weight management and glucose control through GIP and GLP-1 receptor activity in approved products and indications.
• Retatrutide: promising phase 2 human results involving weight and metabolic markers; still investigational.

Growth-hormone signaling research

Tesamorelin has an FDA-approved use for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. That narrow approval should not be generalized to ordinary weight loss. Sermorelin, ipamorelin, and CJC-1295 are discussed in research around growth-hormone signaling, body composition, recovery, and sleep, but they do not share tesamorelin's approved indication or evidence base.

Combining compounds does not automatically combine their proposed benefits. A blend needs evidence as a blend; evidence about each ingredient separately cannot prove that the mixture is effective or safe.

Repair, skin, cognition, and reproductive signaling

BPC-157 and TB-500 are commonly discussed in relation to tissue repair, but much of the cited work is preclinical and does not establish routine human benefit. GHK-Cu has research involving copper signaling, collagen, and skin remodeling, with the route and formulation making an important difference to what evidence can support.

Semax, selank, MOTS-c, kisspeptin-10, and PT-141 involve very different systems—from cognitive or stress signaling to metabolism and reproductive pathways. They should not be treated as one interchangeable category simply because they are peptides.

Glutathione: antioxidant biology does not prove a general vial benefit

Glutathione is a tripeptide made in the body and central to antioxidant chemistry. Small human trials have tested specific glutathione formulations in narrow hospital settings, but those studies do not establish a general wellness, anti-aging, skin, recovery, or disease-treatment benefit for research vials.

Product quality is a separate safety question. On August 5, 2026, FDA posted a recall of certain compounded glutathione 200 mg/mL multi-dose vials after elevated bacterial-endotoxin findings and reported adverse events. That recall does not show that every glutathione product is contaminated, but it underscores why formulation, sterility, lot-specific testing, and intended use cannot be inferred from the ingredient name.

How S7 labels evidence

We use a simple hierarchy: approved labeling for a specific indication; randomized human trials; smaller or early human studies; and preclinical cell or animal research. Language such as “studied for” describes a research question, not a promise of results.